EPI-PHARE Scientific Interest Group in Epidemiology of Health Products, French National Agency for Medicines and Health Products Safety, French National Health Insurance, Saint-Denis, France.
Epidemiology of Childhood and Adolescent Cancers, Centre for Research in Epidemiology and Statistics, French National Institute for Health and Medical Research (INSERM) Joint Research Unit (UMR) 1153, Université Paris-Cité, Paris, France.
JAMA Netw Open. 2024 May 1;7(5):e249429. doi: 10.1001/jamanetworkopen.2024.9429.
Cancer is a leading cause of death among children worldwide. Treatments used for medically assisted reproduction (MAR) are suspected risk factors because of their potential for epigenetic disturbance and associated congenital malformations.
To assess the risk of cancer, overall and by cancer type, among children born after MAR compared with children conceived naturally.
DESIGN, SETTING, AND PARTICIPANTS: For this cohort study, the French National Mother-Child Register (EPI-MERES) was searched for all live births that occurred in France between January 1, 2010, and December 31, 2021 (and followed up until June 30, 2022). The EPI-MERES was built from comprehensive data of the French National Health Data System. Data analysis was performed from December 1, 2021, to June 30, 2023.
Use of assisted reproduction technologies (ART), such as fresh embryo transfer (ET) or frozen ET (FET), and artificial insemination (AI).
The risk of cancer was compared, overall and by cancer type, among children born after fresh ET, FET, or AI and children conceived naturally, using Cox proportional hazards regression models adjusted for maternal and child characteristics at birth.
This study included 8 526 306 children with a mean (SD) age of 6.4 (3.4) years; 51.2% were boys, 96.4% were singletons, 12.1% were small for gestational age at birth, and 3.1% had a congenital malformation. There were 260 236 children (3.1%) born after MAR, including 133 965 (1.6%) after fresh ET, 66 165 (0.8%) after FET, and 60 106 (0.7%) after AI. A total of 9256 case patients with cancer were identified over a median follow-up of 6.7 (IQR, 3.7-9.6) years; 165, 57, and 70 were born after fresh ET, FET, and AI, respectively. The overall risk of cancer did not differ between children conceived naturally and those born after fresh ET (hazard ratio [HR], 1.12 [95% CI, 0.96 to 1.31]), FET (HR, 1.02 [95% CI, 0.78 to 1.32]), or AI (HR, 1.09 [95% CI, 0.86 to 1.38]). However, the risk of acute lymphoblastic leukemia was higher among children born after FET (20 case patients; HR 1.61 [95% CI, 1.04 to 2.50]; risk difference [RD], 23.2 [95% CI, 1.5 to 57.0] per million person-years) compared with children conceived naturally. Moreover, among children born between 2010 and 2015, the risk of leukemia was higher among children born after fresh ET (45 case patients; HR, 1.42 [95% CI, 1.06 to 1.92]; adjusted RD, 19.7 [95% CI, 2.8 to 43.2] per million person-years).
The findings of this cohort study suggest that children born after FET or fresh ET had an increased risk of leukemia compared with children conceived naturally. This risk, although resulting in a limited number of cases, needs to be monitored in view of the continuous increase in the use of ART.
癌症是全球儿童死亡的主要原因。用于医学辅助生殖(MAR)的治疗方法因其潜在的表观遗传干扰和相关的先天性畸形而被怀疑是风险因素。
评估与自然受孕儿童相比,MAR 后出生的儿童患癌症的总体风险和癌症类型风险。
设计、地点和参与者:这项队列研究在法国国家母婴登记处(EPI-MERES)中搜索了 2010 年 1 月 1 日至 2021 年 12 月 31 日期间在法国出生的所有活产儿(并随访至 2022 年 6 月 30 日)。EPI-MERES 是由法国国家卫生数据系统的综合数据构建而成。数据分析于 2021 年 12 月 1 日至 2023 年 6 月 30 日进行。
使用辅助生殖技术(ART),如新鲜胚胎移植(ET)或冷冻胚胎移植(FET)和人工授精(AI)。
使用 Cox 比例风险回归模型,根据出生时的母婴特征对总体和癌症类型进行调整,比较新鲜 ET、FET 或 AI 后出生的儿童与自然受孕的儿童患癌症的风险。
这项研究纳入了 8526306 名儿童,平均(SD)年龄为 6.4(3.4)岁;51.2%为男孩,96.4%为单胎,12.1%为出生时小于胎龄,3.1%患有先天性畸形。共有 260236 名(3.1%)儿童接受 MAR 后出生,其中 133965 名(1.6%)接受新鲜 ET 后出生,66165 名(0.8%)接受 FET 后出生,60106 名(0.7%)接受 AI 后出生。在中位数为 6.7(IQR,3.7-9.6)年的随访中,共确定了 9256 名癌症病例患者;165、57 和 70 名分别出生于新鲜 ET、FET 和 AI 后。与自然受孕的儿童相比,自然受孕的儿童总体癌症风险无差异(危险比 [HR],1.12 [95% CI,0.96 至 1.31])、FET(HR,1.02 [95% CI,0.78 至 1.32])或 AI(HR,1.09 [95% CI,0.86 至 1.38])。然而,FET 后出生的儿童急性淋巴细胞白血病的风险更高(20 名病例患者;HR 1.61 [95% CI,1.04 至 2.50];风险差异 [RD],每百万人口每年 23.2 [95% CI,1.5 至 57.0])与自然受孕的儿童相比。此外,在 2010 年至 2015 年期间出生的儿童中,新鲜 ET 后出生的儿童患白血病的风险更高(45 名病例患者;HR,1.42 [95% CI,1.06 至 1.92];调整后的 RD,每百万人口每年 19.7 [95% CI,2.8 至 43.2])。
这项队列研究的结果表明,FET 或新鲜 ET 后出生的儿童患白血病的风险高于自然受孕的儿童。尽管这种风险导致了有限数量的病例,但鉴于 MAR 的使用不断增加,需要进行监测。